Effect of Sitagliptin And Miglitol on Insulin Therapy in patients with type 2 diabetes

Effect of Sitagliptin And Miglitol on Insulin Therapy in patients with type 2 diabetes - SAMIT study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009950

Enrollment

Registered

2013-03-01

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

sitagliptin50mg/day Sitagliptin50mg/day+miglitol150mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Inpatients with type 2 diabetes 2)fasting plasma glucose from 80 to 140mg/dl using by insulin glargine 3)more than 2 hr postprandial glucose levels 180mg/dl 4)Age>=20

Exclusion criteria

Exclusion criteria: 1)type1 diabetes, 2)severe hepatic dysfunction(AST>100mg/dl,ALT>100mg/dl), 3)severe renal dysfunction(sCr>=2.0mg/dl), 4)past history of abdominal surgery, 5)histry of anaphylaxis of DPP-4 inhibitor and arufa-glucosidase inhibitor, 6)pregnant, intention of becoming pregnant, 7)poor plasma glocose control, 8)Any other condition which the attending physician feels would interfere with the trail participation, 9)steroid treatment or steroid diabetes.

Design outcomes

Primary

Measure	Time frame
Glycemic control and glycemic excursion(variation,mean amplitude of glycemic excursion,24 hour blood glucose AUC, 1- and 2-hour postprandial glucose level by CGMS)	—

Secondary

Measure	Time frame
plasma glucose, serum CPR, actived GLP-1, total GIP and glucagon after diet challenge test	—

Countries

Japan

Contacts

Public ContactRyo Kodera

Okayama University Hospital Center for Innovative Clinical Medicine

kodera@cc.okayama-u.ac.jp086-235-6510

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026